Eli Lilly expedited the availability of baricitinib in India for COVID-19 patients via the signing of a voluntary licensing agreement with Natco Pharma. Based on…
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), recently produced results from a clinical trial the…
This week, Eli Lilly and Company and Incyte announced the publication of the New England Journal of Medicine’s peer-reviewed results from the Adaptive COVID-19 Treatment…
Back in late January, a British artificial intelligence (AI) venture known as BenevolentAIÂ was employed to investigate thousands of potential drug targets against SARS-CoV-2, the virus…
Eli Lilly recently announced more findings suggesting that it’s rheumatoid arthritis drug called baricitinib could improve the condition of patients with severe SARS-CoV-2 infections while…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
